2016-03-10T00:00:00.000-05:00
position,-0.465674
higher risk patients,-0.541735
lung cancer,-0.406811
treatment,-0.426393
E.B. Capital Markets,0.204391
diverse range,0.52021
new revenue,0.546444
ariad pharmaceuticals,-0.0585921
clinical trials,-0.560002
S&P Global Market,0.306882
stocks,-0.465674
proverbial cart,-0.339618
disclosure policy,-0.438396
early stage trials,-0.277873
sales,-0.508263
rare blood,-0.604255
ALK-positive non-small cell,-0.406811
peak sales potential,-0.356407
Motley Fool,-0.471638
welcome source,0.546444
safety concerns,-0.519117
operating expenses,-0.442752
brigatinib,0.431616
brigatinib approval,0.546444
Todd Campbell,-0.253838
cancer drugs,-0.530032
dangerous blood clots,-0.541735
bone marrow diseases,-0.604255
company,0.546444
better investors,0.52021
chronic myeloid leukemia,-0.445975
Iclusig sales,-0.491968
good deal,0.31427
Foolish newsletter services,-0.240471
quarter,-0.602793
